Preview clinical data on a first-in-class triple-hormone metabolic therapy and its potential to change diabetes and obesity treatment approaches.
Key Takeaways
- Findings demonstrated positive outcomes in people living with obesity and type 2 diabetes
- Retatrutide is designed to target three naturally occurring hormones— GIP
- Placebo-controlled trial included 537 participants with recent-onset type 2 diabetes (mean 2.5 years)